Embecta (EMBC) Revenue & Revenue Breakdown
Embecta Revenue Highlights
Latest Revenue (Y)
$1.12B
Latest Revenue (Q)
$272.50M
Main Segment (Y)
Safety
Main Geography (Y)
UNITED STATES
Embecta Revenue by Period
Embecta Revenue by Year
| Date | Revenue | Change |
|---|---|---|
| 2024-09-30 | $1.12B | 0.21% |
| 2023-09-30 | $1.12B | -0.77% |
| 2022-09-30 | $1.13B | -3.05% |
| 2021-09-30 | $1.17B | 7.32% |
| 2020-09-30 | $1.09B | -2.12% |
| 2019-09-30 | $1.11B | - |
Embecta generated $1.12B in revenue during NA 2024, up 0.21% compared to the previous quarter, and up 101.27% compared to the same period a year ago.
Embecta Revenue by Quarter
| Date | Revenue | Change |
|---|---|---|
| 2024-06-30 | $272.50M | -5.12% |
| 2024-03-31 | $287.20M | 3.57% |
| 2023-12-31 | $277.30M | -1.63% |
| 2023-09-30 | $281.90M | -1.47% |
| 2023-06-30 | $286.10M | 3.25% |
| 2023-03-31 | $277.10M | 0.51% |
| 2022-12-31 | $275.70M | 0.40% |
| 2022-09-30 | $274.60M | -5.67% |
| 2022-06-30 | $291.10M | 6.05% |
| 2022-03-31 | $274.50M | -5.12% |
| 2021-12-31 | $289.30M | -3.73% |
| 2021-09-30 | $300.50M | 1.86% |
| 2021-06-30 | $295.00M | 3.80% |
| 2021-03-31 | $284.20M | -0.39% |
| 2020-12-31 | $285.30M | 51.11% |
| 1968-12-31 | $188.80M | - |
Embecta generated $272.50M in revenue during Q3 2024, up -5.12% compared to the previous quarter, and up 98.34% compared to the same period a year ago.
Embecta Revenue Breakdown
Embecta Revenue Breakdown by Product
Annual Revenue by Product
| Product/Service | Sep 24 |
|---|---|
| Product and Service, Other | $10.30M |
| Manufacturing Facility | $12.80M |
| Safety | $129.40M |
Embecta's latest annual revenue breakdown by segment (product or service), as of Sep 24: Safety (84.85%), Manufacturing Facility (8.39%), and Product and Service, Other (6.75%).
Embecta Revenue Breakdown by Country
Annual Revenue by Country
| Country | Sep 24 | Sep 23 | Sep 22 |
|---|---|---|---|
| Non-US | $515.90M | $519.40M | $529.20M |
| UNITED STATES | $607.20M | $601.40M | $600.30M |
Embecta's latest annual revenue breakdown by geography, as of Sep 24: UNITED STATES (54.06%), and Non-US (45.94%).
Quarterly Revenue by Country
| Country | Sep 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| UNITED STATES | $311.00M | $147.60M | $148.60M | $151.80M | $153.90M | $146.40M | $149.30M | $149.90M | $158.00M | $139.80M | - |
| Non-US | $247.60M | $139.60M | $128.70M | $130.10M | $132.20M | $130.70M | $126.40M | $124.70M | $133.10M | $134.70M | $138.40M |
| United States of America, Dollars | - | - | - | - | - | - | - | - | - | - | $150.90M |
Embecta's latest quarterly revenue breakdown by geography, as of Sep 24: UNITED STATES (55.67%), and Non-US (44.33%).
Embecta Peer Comparison by Revenue
| Ticker | Company | Last Year Revenue | Last Quarter Revenue |
|---|---|---|---|
| BAX | Baxter | $14.81B | $3.81B |
| ALC | Alcon | $10.09B | $2.46B |
| RMD | ResMed | $4.69B | $1.22B |
| COO | Cooper Companies | $3.90B | $1.00B |
| ATR | AptarGroup | $3.49B | $909.29M |
| TFX | Teleflex | $2.97B | $764.38M |
| WST | West Pharmaceutical Services | $2.95B | $746.90M |
| NVST | Envista | $2.57B | $884.70M |
| ICUI | ICU Medical | $2.26B | $589.13M |
| HAE | Haemonetics | $1.31B | $336.17M |
| MMSI | Merit Medical Systems | $1.26B | $339.85M |
| EMBC | Embecta | $1.12B | $272.50M |
| ATRC | AtriCure | $399.25M | $115.91M |
| ANGO | AngioDynamics | $303.91M | $67.49M |
| AKYA | Akoya Biosciences | $96.63M | $18.81M |